(VIANEWS) – Halozyme Therapeutics (HALO), FormFactor (FORM), CubeSmart (CUBE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
33.4% sales growth and 153.16% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.58.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 22.94. Meaning, the purchaser of the share is investing $22.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 153.16%.
Volume
Today’s last reported volume for Halozyme Therapeutics is 1090400 which is 17.34% below its average volume of 1319140.
2. FormFactor (FORM)
18.7% sales growth and 13.62% return on equity
FormFactor, Inc. designs, manufactures, and sells probe cards, analytical probes, probe stations, metrology systems, thermal systems, and cryogenic systems to semiconductor companies and scientific institutions. It operates in two segments, Probe Cards and Systems. The company offers probe cards to test various semiconductor device types, including systems on a chip products, mobile application processors, microprocessors, microcontrollers, and graphic processors, as well as radio frequency, analog, mixed signal, image sensor, electro-optical, dynamic random access memory, NAND flash memory, and NOR flash memory devices, as well as computer processor devices; and analytical probes, which are used for a range of applications, including device characterization, electrical simulation model development, failure analysis, and prototype design debugging for universities, research institutions, semiconductor integrated device manufacturers, semiconductor foundries, and fabless semiconductor companies. It also provides probe systems for semiconductor design engineers to capture and analyze accurate data; surface metrology systems for the development, production, and quality control of semiconductor products; thermal subsystems, such as thermal chucks and other test systems used in probe stations and other applications; and precision cryogenic instruments, semiconductor tests, and measurement systems. In addition, the company offers on-site probe card maintenance and service training, seminars, and telephone support services. It markets and sells its products through direct sales force, manufacturers' representatives, and distributors in the United States, Taiwan, South Korea, China, Europe, Japan, Malaysia, Singapore, and internationally. The company was incorporated in 1993 and is headquartered in Livermore, California.
Earnings Per Share
As for profitability, FormFactor has a trailing twelve months EPS of $1.54.
PE Ratio
FormFactor has a trailing twelve months price to earnings ratio of 30.09. Meaning, the purchaser of the share is investing $30.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.62%.
3. CubeSmart (CUBE)
14.8% sales growth and 14.15% return on equity
CubeSmart is a self-administered and self-managed real estate investment trust. The Company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. According to the 2020 Self-Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the United States.
Earnings Per Share
As for profitability, CubeSmart has a trailing twelve months EPS of $1.78.
PE Ratio
CubeSmart has a trailing twelve months price to earnings ratio of 29.9. Meaning, the purchaser of the share is investing $29.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.15%.
Yearly Top and Bottom Value
CubeSmart’s stock is valued at $53.23 at 20:22 EST, below its 52-week high of $55.14 and way above its 52-week low of $33.17.
Moving Average
CubeSmart’s value is higher than its 50-day moving average of $50.55 and way higher than its 200-day moving average of $45.68.
Volume
Today’s last reported volume for CubeSmart is 1091550 which is 9.26% below its average volume of 1203020.
4. AppFolio (APPF)
13.5% sales growth and 41.86% return on equity
AppFolio, Inc., together with its subsidiaries, provides cloud business management solutions for the real estate industry in the United States. The company provides a cloud-based platform that enables users to automate and optimize common workflows; tools that assist with leasing, maintenance, and accounting; and other technology and services offered by third parties. It offers AppFolio Property Manager Core, a platform that provides the basic functionalities required to operate a property management business, as well as serves as a system of record; AppFolio Property Manager Plus, which offers housing management, student housing management, complex accounting, leasing insights, large-scale operations support, role-based permissions, stack integrations, and enhanced customer support services; AppFolio Property Manager Max offers customer relationship management functionality, field customization, customer database functionality, and customer success management services; and AppFolio Investment Manager, a software that provides investment management, asset management, and relationship management solutions. The company also provides value-added services that are designed to enhance, automate, and streamline processes and workflows for property management businesses, such as electronic payment, tenant screening, and insurance services. AppFolio, Inc. was incorporated in 2006 and is headquartered in Santa Barbara, California.
Earnings Per Share
As for profitability, AppFolio has a trailing twelve months EPS of $3.4.
PE Ratio
AppFolio has a trailing twelve months price to earnings ratio of 65.34. Meaning, the purchaser of the share is investing $65.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.86%.
Sales Growth
AppFolio’s sales growth is 26.5% for the ongoing quarter and 13.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 71.7% and 11.4%, respectively.
5. Liberty Media Corporation (FWONK)
12.6% sales growth and 4.13% return on equity
Formula One Group engages in the motorsports business. It holds commercial rights for the world championship, approximately a nine-month long motor race-based competition in which teams compete for the constructors' championship and drivers compete for the drivers' championship. The company was founded in 1950 and is based in Englewood, Colorado. Formula One Group is a subsidiary of Liberty Media Corporation.
Earnings Per Share
As for profitability, Liberty Media Corporation has a trailing twelve months EPS of $1.07.
PE Ratio
Liberty Media Corporation has a trailing twelve months price to earnings ratio of 73.66. Meaning, the purchaser of the share is investing $73.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.13%.
6. iRadimed Corporation (IRMD)
10.4% sales growth and 25.08% return on equity
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Earnings Per Share
As for profitability, iRadimed Corporation has a trailing twelve months EPS of $1.46.
PE Ratio
iRadimed Corporation has a trailing twelve months price to earnings ratio of 34.12. Meaning, the purchaser of the share is investing $34.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.08%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 20, 2024, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 1.2%.
Yearly Top and Bottom Value
iRadimed Corporation’s stock is valued at $49.82 at 20:22 EST, under its 52-week high of $50.93 and way higher than its 52-week low of $36.12.
7. CONMED Corporation (CNMD)
5.6% sales growth and 11.86% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $3.14.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 21.21. Meaning, the purchaser of the share is investing $21.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.
Yearly Top and Bottom Value
CONMED Corporation’s stock is valued at $66.59 at 20:22 EST, way under its 52-week high of $117.27 and above its 52-week low of $61.05.
